Recruiting studies: Met Exon 14 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Phase N/A · 10 location(s) · Novartis Pharmaceuticals · NCT05703516 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Phase 3 · 1 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT05989542 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224 DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Phase 2/Phase 3 · 17 location(s) · Cancer Research UK · NCT06988475 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 44 location(s) · Haihe Biopharma Co., Ltd. · NCT04270591 Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340 Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea
Phase 3 · 29 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06908993

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.